

Effect Of Statins On Pulmonary Functions in COPD Patients

Thesis

*Submitted for Partial Fulfillment of Master Degree
in Chest Diseases and Tuberculosis*

By

Yasmin Fahd Salah El Din

M.B.B.Ch

Supervised by

Prof. Mohammed Sherif Elbouhy

Professor of Chest Diseases

Faculty of Medicine, Ain Shams University

Dr. Eman Ramzy Ali

Lecturer of Chest Diseases

Faculty of Medicine, Ain Shams University

Dr. Ashraf Adel Gomaa

Lecturer of Chest Diseases

Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

2010

Acknowledgement

*First of all, I thank **ALLAH** who gave me the power to finish this work.*

*I would like to express my deepest gratitude and greatest appreciation to **Prof. Dr. Mohammed Sherif Elbouhy**, Professor of Chest Diseases, Faculty of Medicine, Ain Shams University, for his guidance, supervision and support.*

*My deepest thanks & infinite gratitude to **Dr. Eman Ramzy Ali**, Lecturer of Chest Diseases, Faculty of Medicine, Ain Shams University, for her guidance, cooperation and patience.*

*I would like to extend cordial appreciation & infinite gratitude to **Dr. Ashraf Adel Gomaa**, Lecturer of Chest Diseases, Faculty of Medicine, Ain Shams University who was very kind and patient to me, saving no time or effort helping me with this work.*

*Also, I would like to express special thanks and gratitude to **Epico Company for drug industry** which supplied this study with the materials needed to finish this work.*

List of Contents

	Page
Introduction	1
Aim of the Work	3
Review of Literature:	
<i>Chronic Obstructive Pulmonary Disease (COPD)</i>	4
▪ Definitions	4
▪ Burden of COPD	5
▪ Risk Factors	10
▪ Pathogenesis, Pathology and Pathophysiology	17
▪ Clinical Features of COPD	32
▪ Investigations	37
▪ Staging of COPD	44
▪ Management of COPD	47
<i>Statins</i>	61
▪ History	61
▪ Chemistry	62
▪ Members	63
▪ Mechanism of action	65

▪ Statins and inflammation	66
▪ Absorption, fate and excretion	67
▪ Adverse effects	69
▪ Indications and uses	71
▪ Statin effects on pulmonary inflammation in COPD	73
Subjects and Methods	77
Results	85
Discussion	98
Summary	105
Conclusions	108
Recommendations	109
References	110
Arabic Summary	—

List of Figures

Figure No.	Title	Page No.
(1)	Pathological Changes of the Central Airways in COPD	20
(2)	Pathological Changes of the Peripheral Airways in COPD	21
(3)	Normal spirogram and spirogram typical of patients with moderate COPD	40
(4)	Members of Statins	63,64
(5)	Comparison between all PFT parameter before and after treatment with Atorvastatin among all participants	89
(6)	Comparison between all PFT parameter before and after treatment with Atorvastatin among mild COPD cases	90
(7)	Comparison between all PFT parameter before and after treatment with Atorvastatin among moderate COPD cases	91

(8)	Comparison between all PFT parameter before and after treatment with Atorvastatin among severe COPD cases	92
(9)	Comparison between mild, moderate and severe COPD regarding the change in PFT parameter before and after treatment with Atorvastatin	93
(10)	Correlations between FEV1 and other PFT parameters after Treatment with Atorvastatin	94
(11)	Correlations between FVC and other PFT parameters after Treatment with Atorvastatin	95
(12)	Correlations between FEV1/FVC and other PFT parameters after Treatment with Atorvastatin	96
(13)	Correlations between FEF25-75 and other PFT parameters after Treatment with Atorvastatin	97

List of Tables

Table No.	Title	Page No.
(1)	The Egyptian Society of Chest Diseases and Tuberculosis (ESCT) classification of COPD (2003)	45
(2)	Global initiative for Chronic Obstructive Lung Disease, 2009 classification	46
(3)	Stepwise therapy at Each Stage of COPD according to GOLD 2009	50
(4)	Description of FEV1, FVC, FEF25-75 and FEV1/FVC before and after the treatment with Atorvastatin among all study participants	85
(5)	Description of FEV1, FVC, FEF25-75 and FEV1/FVC before and after the treatment with Atorvastatin among mild COPD patients	86
(6)	Description of FEV1, FVC, FEF25-75 and FEV1/FVC before and after the treatment with Atorvastatin among moderate COPD patients	87

(7)	Description of FEV1, FVC, FEF25-75 and FEV1/FVC before and after the treatment with Atorvastatin among severe COPD patients	88
(8)	Comparison between all PFT parameter before and after treatment with Atorvastatin among all participants	89
(9)	Comparison between all PFT parameter before and after treatment with Atorvastatin among mild COPD cases	90
(10)	Comparison between all PFT parameter before and after treatment with Atorvastatin among moderate COPD cases	91
(11)	Comparison between all PFT parameter before and after treatment with Atorvastatin among severe COPD cases	92
(12)	Comparison between mild, moderate and severe COPD regarding the change in PFT parameter before and after treatment with Atorvastatin	93

(13)	Correlations between FEV1 and other PFT parameters after Treatment with Atorvastatin	94
(14)	Correlations between FVC and other PFT parameters after Treatment with Atorvastatin	95
(15)	Correlations between FEV1/FVC and other PFT parameters after Treatment with Atorvastatin	96
(16)	Correlations between FEF25-75 and other PFT parameters after Treatment with Atorvastatin	97

List of Abbreviation

ASTEROID trail	A clinical trial published in 2006 that shows the effects of statins on atherosclerosis
BEC	Bronchial Epithelial Cells
BODE	body mass index, airflow obstruction, dyspnea, and exercise capacity
BTS	British Thoracic Society
CAL	Chronic Airflow Limitation
CD4,CD8	Cluster of Differentiation (is a glycoprotein expressed on the surface of T helper cells, regulatory T cells, monocytes and macrophages).
CHD	Coronary Heart Disease
COPD	Chronic Obstructive Pulmonary Disease
CRP	C-reactive protein
CT	Computed tomography
CXP3A4	3A4 isoform of cytochrome P450
Cyclic AMP	Cyclic Adenosine monophosphate
DALY	The Disability-Adjusted Life Year
<i>ESCT</i>	The Egyptian Society of Chest Diseases and Tuberculosis
ETS	Environmental Tobacco Smoke
FDA	Food and Drug Administration
FEF₂₅₋₇₅	Forced expiratory flow 25% to 75%.
FEV₁	Forced expiratory volume in first second.
FVC	Forced vital capacity

GM-CSF	Granulocyte-macrophage Colony Stimulating Factor
GTPase	Enzyme bind and hydrolyze guanosine triphosphate
GOLD	Global Initiative for Chronic Obstructive Lung Disease
H. influenza	Hemophilus influenza
HMG-CoA reductase	3-hydroxy-3-methylglutaryl coenzyme A reductase
HPS	Heart Protection Study
ICU	Intensive Care Unit
IL-1,6,8	Interleukin-1,6,8
KCO	transfer coefficient
KPa	Kilopascal (a unit of pressure measurement)
LDL	low density lipoprotein
LTB4	leukotriene B4
LVRS	Lung Volume Reduction Surgery
M₂ receptor	Muscarinic receptor
MENA	Middle East and North Africa region
M. catarrhalis	Moraxella catarrhalis
mEPHX1	microsomal epoxide hydrolase 1
NHANES III	The third National Health And Nutrition Examination Survey
NIPPV	Noninvasive intermittent positive pressure ventilation
PaO₂	Partial pressure of oxygen
PaCO₂	Partial pressure of carbon dioxide

PH	Pulmonary Hypertention
P_{emax}	Maximum expiratory pressure
PFT	Pulmonary Function Tests
P_{imax}	Maximum inspiratory pressure
S.pneumoniae	streptococcus pneumoniae
SaO₂	Oxygen saturation
SREBPs	Sterol Regulatory Element Binding Proteins
TLCO	Carbon monoxide Transfer Factor
TGF-1	Transforming Growth Factor beta 1
TNF-α	Tumor Necrosis Factor alpha
μg	Microgram
V_A/Q	Ventilation/ Perfusion ratio
WHO	World Health Organization
YLD	Years of Living with Disability

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases. Worldwide cigarette smoking is the overwhelming risk factor for COPD, although in many countries, air pollution resulting from the burning of wood and other biomass fuels has also been identified as a COPD risk factor (*GOLD, 2009*).

Although COPD affects the lungs, it also produces significant extrapulmonary effects that may contribute to disease severity in individual patients (*Agusti, 2005*).

A diagnosis of COPD should be considered in any patient who has symptoms of cough, sputum production, or dyspnea, and/or a history of exposure to risk factors for the disease (*GOLD, 2009*).

Statins"3-hydroxy-3-methyl-glutaryl-coenzyme-A (HMG- CoA) reductase inhibitors", are a class of drugs that lower cholesterol level in people with or at risk of

cardiovascular diseases. They lower cholesterol by inhibiting the enzyme HMG-CoA reductase which is the rate-limiting enzyme of mevalonate pathway of cholesterol synthesis (*Endo, 1992*).

Statins are used for their lipid lowering characteristics but also appear to have anti-inflammatory and immunomodulatory properties which could possibly influence inflammatory airway disease (*Keddissi et al., 2007*).

Previous studies assessed evidence for disease modifying effects of statin treatment in patients with COPD. Outcomes associated with treatment with statins included decreased COPD related mortality, reduction in incidence of respiratory related urgent care, fewer COPD exacerbations, fewer intubations for COPD exacerbations and attenuated decline in pulmonary function (*Dobler et al., 2009*).

Aim of the Work

The aim of this work is to assess the effect of statins on pulmonary functions in COPD patients.